Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection

This study has been completed.
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
Archivel Farma S.L.
ClinicalTrials.gov Identifier:
NCT01136161
First received: May 31, 2010
Last updated: January 23, 2013
Last verified: January 2013
  Purpose

The aim of the trial is to assess the safety, tolerability and immunogenicity of two doses of RUTI® vaccine administered four weeks apart after one month pre-treatment with INH.

The trial will be double-blinded, randomized and placebo-controlled with 96 subjects (48 HIV- and 48 HIV+ subjects).

Three different RUTI® doses and placebo will be tested, randomizing assigned both in HIV+ and HIV- subjects. Each subject will be randomized to receive one of the four treatments (placebo, 5, 25, 50 μg), after completion of one month INH pre-treatment (one tablet of 300mg/day, vp.o.). Each subject will receive two administrations of the same treatment, 28 days apart. Subjects will be monitored until one month after the second inoculation with RUTI®.


Condition Intervention Phase
Latent Tuberculosis Infection
Tuberculosis
Biological: RUTI
Biological: RUTI Matching Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection

Resource links provided by NLM:


Further study details as provided by Archivel Farma S.L.:

Primary Outcome Measures:
  • Local tolerability [ Time Frame: 84 days ] [ Designated as safety issue: Yes ]

    The investigator will evaluate the site of injection for redness, pain, swelling, and induration and functional limitation.

    Redness, swelling and induration will be evaluated and recorded on the CRF as: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. If present, the extent of the reaction will be measured in mm. Pain will be recorded, after questioning the subjects, by means of a Visual Analogue Scale (VAS from 0 to 100). The presence of abscess, ulceration or necrosis will also be evaluated, measured and adequately documented.


  • Focal Tolerability [ Time Frame: 84 days ] [ Designated as safety issue: Yes ]
    Evaluation of the hilar lymph nodes for inflammation: An un-contrasted thoracic computerised tomographic scan will be performed to evaluate the change in size of the hilar lymph nodes.

  • Systemic tolerability [ Time Frame: 84 days ] [ Designated as safety issue: Yes ]
    Body temperature ≥38ºC, asthenia, sweating, malaise, headache, dizziness, nausea, myalgia, arthralgia, rash and generalised pruritus

  • Vital Signs and physical examination [ Time Frame: 84 days ] [ Designated as safety issue: Yes ]
    Blood pressure (systolic and diastolic), pulse, respiratory rate, body temperature and full physical examination will be assessed

  • ECG [ Time Frame: 84 days ] [ Designated as safety issue: Yes ]
    The following ECG parameters will be measured: Bits Frequency Heart rate, PR, QRS, QT and QTc (Bazett) intervals. Any other anomaly on the ECG (such as U wave, ischaemia, rhythm and conduction disturbances) will be evaluated by the investigator

  • Laboratory Tests [ Time Frame: 84 days ] [ Designated as safety issue: Yes ]
    Blood samples for serum chemistry and haematology and urine sample for urinalysis will be taken under fasting conditions for evaluation of laboratory safety parameters


Secondary Outcome Measures:
  • Immunogenicity [ Time Frame: 63 days ] [ Designated as safety issue: No ]

    Samples to perform immunogenicity testing will be collected at specified visits. Cellular mediated immunity (ELISPOT and ELISA techniques), IFN-gama Spot Forming Units after stimulation for 18 hours with five stimuli, WHO assay (stimulating whole blood 7days with PPD) and TIGRA (TSPOT TB assay).

    Peripheral blood mononuclear cells will be frozen for future immune assays. Sera will be frozen to be further tested for the antibody-mediated immunity against M.tuberculosis antigens



Enrollment: 95
Study Start Date: June 2010
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RUTI 5 micrograms of FCMtb in HIV -
n=12
Biological: RUTI
dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
Experimental: RUTI 25 micrograms of FCMtb in HIV -
n=12
Biological: RUTI
dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
Experimental: RUTI 50 micrograms of FCMtb in HIV -
n=12
Biological: RUTI
dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
Placebo Comparator: RUTI Matching Placebo in HIV -
n=12
Biological: RUTI Matching Placebo
Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
Experimental: RUTI 5 micrograms of FCMtb in HIV +
n=12
Biological: RUTI
dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
Experimental: RUTI 25 micrograms of FCMtb in HIV +
n=12
Biological: RUTI
dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
Experimental: RUTI 50 micrograms of FCMtb in HIV +
n=12
Biological: RUTI
dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
Placebo Comparator: RUTI Matching Placebo in HIV +
n=12
Biological: RUTI Matching Placebo
Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.

Detailed Description:

RUTI is a therapeutic vaccine made from virulent M.tuberculosis bacteria, grown in stressful conditions, fragmented, detoxified, heat inactivated (FCMtb) and liposomed. RUTI provides a strong humoral and cellular immune response against antigens from active growing and latent bacilli but also against structural antigens, as it has been proved in animal models of latent tuberculosis infection and in phase I clinical trial of Healthy Volunteers. The vaccine has been designed to be used against Latent Tuberculosis Infection as a therapeutic vaccine after 1-month of chemotheraputic treatment, instead the current treatment based on 6-9 months of chemotherapy.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Asymptomatic adult aged 18 up to 50 years.
  2. No evidence of active TB (Section 8).
  3. No clinically significant finding at the discretion of the investigator.
  4. Willingness to undergo an HIV test.
  5. Resident in or near trial site for the duration of the trial.
  6. Willingness to allow the investigators to discuss the patient's medical history with his usual doctor or HIV physician.
  7. No donation of blood for 56 days prior to screening and agreement to refrain from blood donation during the trial.
  8. Willing and able to provide written informed consent.
  9. Positive tuberculin skin test (TST +), (≥5 mm induration) and Quantiferon TB Gold positive result (according to manufacturers instructions).
  10. Reliable contraception to be used by female subjects during the clinical trial.
  11. Additional inclusion criteria for HIV+ groups:

    • HIV antibody positive.
    • CD4 count ≥350 cells/mL3 on a single CD4 count at the period of screening.
    • Subjects on anti-retroviral treatment can be included if clinically stable.

Exclusion Criteria:

  1. Any deviation from the normal range in biochemistry or haematology blood tests or in urine analysis that is considered to be clinically significant at the discretion of the investigator. Values of Hb, WCC, platelet count, AST/ALT and creatinine should be in a normal range accordingly to the normal laboratory values.
  2. Use of any investigational or non-registered drug, vaccine, or medical device other than the trial vaccine within 30 days prior to dosing of trial vaccine, or planned use during the trial period.
  3. Administration of chronic (defined as more than 14 days) immunosuppressive drugs within six months of vaccination and required throughout the duration of the trial (for corticosteroids this means prednisolone or equivalent at ≥ 0.5 mg/kg/day).
  4. Female of child bearing potential who intends to become pregnant during the trial.
  5. Females who are pregnant, lactating, or of child bearing potential with a blood HCG positive result 24-48 hours at the screening period, or prior to every injection of RUTI®.
  6. Any AIDS defining illness according to the CDC classification system for HIV infection.
  7. Presence of active (previously undiagnosed) TB or being on TB treatment.
  8. Suspected or known current alcohol abuse (alcohol intake questionnaire.
  9. Suspected or known substance abuse.
  10. Presence of any underlying disease, specifically autoimmune disease, asthma, angioedema, bleeding disorders, uncontrolled hypertension and diabetes, and any other disease that compromises the diagnosis and evaluation of response to the vaccine, excluding HIV.
  11. Administration of immunoglobulins and/or any blood products within three months prior to the planned administration of the vaccine.
  12. Any history of anaphylaxis in reaction to vaccination and/or other medication.
  13. Investigator assessment of lack of understanding or willingness to participate and comply with all requirements of the trial protocol.
  14. Any other finding which in the opinion of the investigator would significantly increase the risk of having an adverse outcome from participating in the trial.
  15. Exclusion criteria relating to INH pre-treatment

    • Weight less than 40 kg.
    • Known or suspected hypersensitivity to INH.
    • Self reported chronic liver disease or symptoms suggesting active hepatitis (jaundice, nausea, vomiting, right upper quadrant pain, dark urine, pale stools).
    • Alcohol use exceeding 28 units per week (men) or 21 units per week (women) (see alcohol intake questionnaire, Appendix 17.2).
    • History of convulsions.
    • History of psychosis.
    • Peripheral neuropathy grade 2 or greater.
    • Three months post-partum.
    • Concomitant medication with phenytoin, carbamazepine; warfarin; theophylline; disulfiram; selective serotonin re-uptake inhibitor antidepressants (e.g. citalopram, fluoxetine, paroxetine, sertraline); oral ketoconazole or itraconazole.
  16. Additional exclusion criterion for HIV negative groups:

    • Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia.

  17. Additional exclusion criterion for HIV+ groups • CD4 count < 350 cells/mL3.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01136161

Locations
South Africa
Parexel Int. Bloemfontein
Bloemfontein, South Africa, 9301
Parexel Int. George
George, South Africa, 6529
Parexel Int. Port Elizabeth
Port Elizabeth, South Africa, 6045
Sponsors and Collaborators
Archivel Farma S.L.
Parexel
Investigators
Principal Investigator: André S Nell, MD Parexel Int. Bloemfontein
Study Chair: Pere Joan Cardona, MD, PhD Archivel Farma S.L.
  More Information

Additional Information:
Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Archivel Farma S.L.
ClinicalTrials.gov Identifier: NCT01136161     History of Changes
Other Study ID Numbers: RUTISAPH2
Study First Received: May 31, 2010
Last Updated: January 23, 2013
Health Authority: South Africa: Medicines Control Council

Keywords provided by Archivel Farma S.L.:
LTBI (Latent Tuberculosis Infection)
TB (Tuberculosis)
Vaccine

Additional relevant MeSH terms:
Communicable Diseases
Infection
Latent Tuberculosis
Tuberculosis
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections

ClinicalTrials.gov processed this record on October 23, 2014